Electrocore Stock Price, News & Analysis

electroCore announced that CEO Dan Goldberger will present at the 2022 Maxim Virtual Growth Conference from March 28-30, 2022. The presentation will be available on-demand, providing insights into the company's advancements in bioelectronic medicine. electroCore focuses on non-invasive vagus nerve stimulation therapy for the treatment of conditions like migraines and cluster headaches. The company's solutions aim to improve patient outcomes in neurology. Stakeholders can access the presentation and more information via the provided link.

electroCore reported a significant 56% increase in full-year net sales for 2021, totaling approximately $5.5 million, compared to $3.5 million in 2020. The fourth quarter recorded net sales of $1.5 million, marking a 61% growth year-over-year. Cash balances stood at $34.7 million as of December 31, 2021. The company has launched new online purchasing platforms and achieved a 69% increase in sales to the VA and DoD. However, a GAAP net loss of $17.2 million was reported for the year, down from $23.5 million in 2020.

electroCore, Inc. (Nasdaq: ECOR) announced the appointment of Julie Bruzzone Goldstein and Tricia Wilber to its Board of Directors, effective March 15, 2022. This move aims to bolster the company's marketing and brand strategy as it focuses on direct-to-consumer initiatives. The appointments follow the resignation of Dr. Stephen Ondra, who is transitioning to a new role, and Michael Atieh, who will not seek re-election. Both Goldstein and Wilber bring extensive marketing expertise from leading organizations, including Disney and JIVE Records, which could enhance electroCore’s growth prospects.

electroCore, a bioelectronic medicine company (NASDAQ: ECOR), announced its participation in the 34th Annual Roth Conference on March 14, 2022, at 8:30 AM PDT. The presentation will be accessible to investors who can register online. Following the event, a webcast replay will be available on the company's investor website. The company focuses on improving patient outcomes through its non-invasive vagus nerve stimulation therapy, targeting conditions such as migraines and cluster headaches.

electroCore, Inc. (Nasdaq: ECOR) will report its financial results for Q4 and the year ending December 31, 2021, on March 10, 2022. A conference call will follow at 4:30 PM EST to discuss results and answer questions. The company's focus is on non-invasive vagus nerve stimulation therapy for treating conditions like migraines and cluster headaches.

electroCore (Nasdaq: ECOR) announced promising results from clinical trials presenting at the 2022 International Stroke Conference. The trials explored the use of non-invasive Vagus Nerve Stimulation (nVNS) for treating acute stroke. Key findings showed a 65.9% reduction in relative ischemic lesion growth for nVNS compared to sham treatment. The trials indicated that nVNS was administered safely and met both primary and secondary endpoints. The company anticipates further research to establish nVNS's efficacy in stroke treatment.

electroCore (Nasdaq: ECOR) has completed enrollment for the TRANSIT study, a 97-patient, randomized, sham-controlled trial investigating non-invasive vagal nerve stimulation (nVNS) to alleviate postoperative ileus after colorectal surgery. Conducted in the UK, this study aims to improve recovery times and reduce healthcare costs associated with ileus, which affects 10-20% of colorectal surgery patients. Results from this study are anticipated later this year and will be presented at a medical congress.

electroCore (Nasdaq: ECOR) announced the presentation of three abstracts related to non-invasive vagus nerve stimulation (nVNS) for acute stroke treatment at the American Heart Association’s 2022 International Stroke Conference on February 9-11, 2022. Key presentations include a moderated poster on the acute treatment of ischemic or hemorrhagic stroke and two poster presentations investigating nVNS's effects on brain injury and ischemic stroke in rats. electroCore focuses on improving patient outcomes through its nVNS therapy, already FDA cleared for treating various types of headaches.

electroCore anticipates a 55% revenue increase for full-year 2021, projecting approximately $5.5 million compared to $3.5 million in 2020. The company is enhancing consumer access to its gammaCore therapy through new e-commerce platforms in the U.S. and U.K., alongside initiatives like gConcierge and gCDirect programs targeting healthcare providers. Revenue from government channels, including the VA and DoD, is expected to grow over 60%. The company also plans to broaden its clinical programs and explore acquisitions to further growth.